October 8, 2009 (FinancialWire) — Sangamo BioSciences, Inc. (NASDAQ: SGMO) has priced a public offering of three million shares of its common stock. Jefferies & Co. (NYSE: JEF) is acting as sole book-running manager.

The company has granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments. The offering is scheduled to close on or about October 13.

Richmond, California-based Sangamo BioSciences is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.

The company’s most advanced ZFP Therapeutic development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS.

Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson’s disease and monogenic diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.